Gene therapy for proliferative ocular diseases.
Proliferative ocular diseases encompass a wide variety of pathological processes with adverse cellular differentiation, proliferation and migration as common features. Pathologies may involve neovascular responses associated with diabetic retinopathy, retinopathy of prematurity or age-related macular degeneration. These diseases are quite prevalent and account for substantial visual impairment and blindness worldwide. Although treatment strategies are largely surgical, advances in our understanding of the proteins crucial to cell transdifferentiation, proliferation and migration, along with better gene transfer techniques, have greatly increased the potential for biological treatment options. In this report, the most common proliferative ocular vascular diseases and existing therapeutic modalities will be reviewed and an overview of possible gene therapy options will be discussed, along with potential candidate genes.
Casey Eye Institute, OHSU, 3375 SW Terwilliger BLVD, Portland, OR 97239, USA.
Trevor J
TJ
McFarland
Yi
Y
Zhang
Binoy
B
Appukuttan
J Timothy
JT
Stout
D000256:Adenoviridae / Q000235:genetics; D000368:Aged; D002454:Cell Differentiation; D002455:Cell Division; D002465:Cell Movement; D004274:DNA, Recombinant / Q000627:therapeutic use; D000229:Dependovirus / Q000235:genetics; D003930:Diabetic Retinopathy / Q000628:therapy; D005128:Eye Diseases / Q000473:pathology / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008081:Liposomes; D008268:Macular Degeneration / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000628:therapy; D034622:RNA Interference; D016337:RNA, Catalytic / Q000627:therapeutic use; D012178:Retinopathy of Prematurity / Q000628:therapy; D012190:Retroviridae / Q000235:genetics
D004274:DNA, Recombinant; D008081:Liposomes; D016337:RNA, Catalytic